Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome.
Publication
, Conference
Raza, A; Fenaux, P; Erba, H; Mandelli, F; Schiller, G; Larson, R; Denzlinger, C; Greenberg, P; Muus, P; Gotlib, J; Bennett, J; Leopold, L ...
Published in: BLOOD
November 16, 2002
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2002
Volume
100
Issue
11
Start / End Page
795A / 795A
Location
PHILADELPHIA, PENNSYLVANIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
44th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Raza, A., Fenaux, P., Erba, H., Mandelli, F., Schiller, G., Larson, R., … Berger, M. (2002). Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome. In BLOOD (Vol. 100, pp. 795A-795A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
Raza, A., P. Fenaux, H. Erba, F. Mandelli, G. Schiller, R. Larson, C. Denzlinger, et al. “Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome.” In BLOOD, 100:795A-795A. AMER SOC HEMATOLOGY, 2002.
Raza A, Fenaux P, Erba H, Mandelli F, Schiller G, Larson R, et al. Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome. In: BLOOD. AMER SOC HEMATOLOGY; 2002. p. 795A-795A.
Raza, A., et al. “Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome.” BLOOD, vol. 100, no. 11, AMER SOC HEMATOLOGY, 2002, pp. 795A-795A.
Raza A, Fenaux P, Erba H, Mandelli F, Schiller G, Larson R, Denzlinger C, Greenberg P, Muus P, Gotlib J, Bennett J, Leopold L, Lejeune C, Richie M, Berger M. Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome. BLOOD. AMER SOC HEMATOLOGY; 2002. p. 795A-795A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2002
Volume
100
Issue
11
Start / End Page
795A / 795A
Location
PHILADELPHIA, PENNSYLVANIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
44th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology